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Abstract
Background: An Nrf2-dependent response is a central protective mechanism against oxidative stress. We propose
that particular genetic variants of the Nrf2 gene may be associated with a rapid forced expiratory volume in one
second (FEV1) decline induced by cigarette smoking.
Methods: We conducted a retrospective cohort study of 915 Japanese from a general population. Values of annual
decline in FEV1 were computed for each individual using a linear mixed-effect model. Multiple clinical
characteristics were assessed to identify associations with annual FEV1 decline. Tag single-nucleotide
polymorphisms (SNPs) in the Nrf2 gene (rs2001350, rs6726395, rs1962142, rs2364722) and one functional SNP
(rs6721961) in the Nrf2 promoter region were genotyped to assess interactions between the Nrf2 polymorphisms
and smoking status on annual FEV1 decline.
Results: Annual FEV1 decline was associated with smoking behavior and inversely correlated with FEV1/FVC and
FEV1 % predicted. The mean annual FEV1 declines in individuals with rs6726395 G/G, G/A, or A/A were 26.2, 22.3,
and 20.8 mL/year, respectively, and differences in these means were statistically significant (pcorr = 0.016). We also
found a significant interaction between rs6726395 genotype and smoking status on the FEV1 decline (p for
interaction = 0.011). The haplotype rs2001350T/rs6726395A/rs1962142A/rs2364722A/rs6721961T was associated with
lower annual decline in FEV1 (p = 0.004).
Conclusions: This study indicated that an Nrf2-dependent response to exogenous stimuli may affect annual FEV1
decline in the general population. It appears that the genetic influence of Nrf2 is modified by smoking status,
suggesting the presence of a gene-environment interaction in accelerated decline in FEV1.
Background
Among pulmonary function test (PFT) measurements,
forced expiratory volume in one second (FEV1)i st h e
most reproducible [1]. Therefore, it is suitable for analyz-
ing changes in pulmonary function over time. Accelerated
decline in FEV1 is considered as an important predictor
for the development of inflammatory obstructive lung dis-
eases, such as asthma and chronic obstructive pulmonary
disease (COPD) [2,3]. A rapid decline in FEV1 may be
affected by multiple factors, including environmental and
genetic factors.
The most important environmental factor for FEV1
decline is cigarette smoking. In their landmark study,
Fletcher et al. [4] demonstrated that smokers had a steeper
decline in FEV1 than non-smokers. Subsequent studies
have revealed that the rate of decline in FEV1 depends on
pack-years smoked and that the accelerated decline in
FEV1 in smokers slows to normal rates of decline upon
smoking cessation [4-6]. Cigarette smoke contains high
concentrations of oxidants, including reactive oxygen spe-
cies and reactive nitrogen species [7]. Oxidative stress due
to cigarette smoking promotes direct injury to airway
epithelium, expression of genes encoding proinflammatory
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any medium, provided the original work is properly cited.mediators, and protease/antiprotease imbalance [8], all of
which induce chronic inflammation in the lung of smokers
that results in deterioration of lung function.
However, only 10-15% of smokers develop a severe
impairment of lung function [4]. In addition to environ-
mental factors, genetic determinants play an important
role in rapid decline in lung function. A pedigree-based
study has shown that FEV1 levels have a heritability that
is independent of cigarette smoking and disease status
such as asthma [9]. Furthermore, recent large-scale gen-
ome-wide association studies have identified several loci
associated with FEV1 and the FEV1/forced vital capacity
(FVC) ratio [10,11].
It is possible that oxidant/antioxidant imbalance in the
lungs of smokers results in an accelerated loss of lung
function. Nrf2 is a major regulator of the antioxidant
response [12]. Nrf2 regulates the expression of several
genes encoding antioxidant and detoxification proteins
[13]. In animal models, Nrf2 plays an important role in
reducing inflammation associated with elastase-induced
emphysema [14]. In human studies, attenuation of Nrf2
due to the down-regulation of the Nrf2 mRNA has been
detected in alveolar macrophages of COPD patients
[15]. Moreover, 3 single-nucleotide polymorphisms
(SNPs) in the promoter region of the Nrf2 gene have an
influence on the gene’s transcriptional activity, and one
of these SNPs is associated with the development of
acute lung injury [16]. Recently, one SNP (rs2364723) in
the first intron of Nrf2 has been shown to be related to
a lower FEV1 [17]. All of these findings indicate that an
Nrf2-dependent adaptive response is important in inhi-
biting the oxidant-induced lung inflammation that
results in a rapid decline in lung function.
Therefore, we conducted a longitudinal retrospective
cohort study of a general Japanese population in order
to analyze associations between Nrf2 polymorphisms
and annual decline in FEV1. We also assessed whether
an interaction between the Nrf2 polymorphisms and
smoking status affects FEV1 decline.
Methods
Subjects
A retrospective cohort study was conducted. We recruited
1,507 full-blooded Japanese subjects from a general popu-
lation who visited the Tsukuba Medical Center for annual
health checkup from June 2008 to May 2009 (Figure 1).
Detailed information on the cohort is available in a pre-
vious report [18]. The individuals completed question-
naires concerning respiratory health, medical history,
lifestyle, and exposure to environmental irritants (e.g.
cigarette smoke, allergens, and air pollution). All 1,507
subjects participated in a medical interview, a physical
examination, routine blood studies, a chest roentgen-
ogram, and PFTs. Based on detailed data from these
analyses, we excluded 36 subjects from the study because
of a preexisting lung ailment; 12 were diagnosed as having
preexisting tuberculosis, 3 also had a diagnosis of asthma,
and 24 individuals with asthma or COPD who had been
treated by inhaled corticosteroids, leukotriene receptor
antagonists, and/or bronchodilators such as b-adrenocep-
tor stimulants and anticholinergic agents. From among
the remaining 1,471 subjects, 915 participants who took at
least 4 valid PFT measurements over a period of at least 4
years were selected for this study in order to ensure a reli-
able estimate of longitudinal decline in FEV1.T h ef i n a l
study population of 915 participants included 47 subjects
with asthmatic history who had not taken asthma medica-
tion during the retrospective study period.
The Institutional Review Boards of the University of
Tsukuba (IRB No. 136) and the Tsukuba Medical Cen-
ter (IRB No. 2008-01-31) approved the study, and each
subject provided written informed consent.
Pulmonary Function Test (PFT)
Spirometry was performed with an electronic spirometer
(Autospiro SYSTEM7; Minato Medical Science Co.,
Ltd., Osaka, Japan) according to the standards recom-
mended by the Japanese Respiratory Society (JRS) [19].
The patients performed the maneuvers without any
bronchodilators. The highest value for the sum of FVC
and FEV1 was selected as the measurement for each
PFT. FVC and FEV1 were expressed as a percentage of
predicted values approved by the JRS [19]. All available
longitudinal data for each participant were collected ret-
rospectively to estimate the annual decline in FEV1.
Single-Nucleotide Polymorphism (SNP) Selection and
Genotyping
Using JPT (Japanese in Tokyo, Japan) genotype data (Pha-
seIII/Rel#2, Feb09, on NCBI B36 assembly, dbSNP b126)
from the International HapMap project http://hapmap.
org/, four tag SNPs (rs2001350, rs6726395, rs1962142,
rs2364722) were identified in the 34.38 kb Nrf2 gene
region (chromosome 2, position 177,803,285-177,837,663).
We used the multi-marker predictor method implemented
in the Tagger program [20]. Tag set was generated using a
threshold r
2 of 0.8 and a minor allele frequency of > 0.1.
Genomic DNA was extracted from samples of whole
blood from each of the 915 participants by an automated
DNA extraction system (QuickGene-610L, FUJIFILM,
Tokyo, Japan). Genotyping of these 4 bi-allelic SNPs were
attempted for each participant by the pre-designed Taq-
Man allele-specific polymerase chain reaction (PCR) assays
according to the manufacturer’s instruction (Applied Bio-
systems, Foster City, CA).
It has been reported that 3 SNPs (rs6721961,
rs6706649, and rs35652124) located in the promoter
region of the Nrf2 gene affect the transcriptional activity
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for each participant by theT a q M a nt e c h n i q u eu s i n ga
pair of primers and a pair of oligonucleotide probes
designed and synthesized by Applied Biosystems. The
sequences of the primers were as follows: forward, 5’-
CAGTGGGCCCTGCCTAG-3’;r e v e r s e ,5 ’-TCAGGGT-
GACTGCGAACAC-3’. The TaqMan fluorescence-
labeled oligonucleotide probes were 5’-[VIC]-TGGA-
CAGCGCCGGCAG-3’ and 5’-[FAM]-TGTGGACAG
CTCCGGCAG-3’. Because rs6706649 and rs35652124
are only 2 base pairs apart, the allele-specific probe
technique was not appropriate for genotyping. Instead,
for these 2 SNPs, direct DNA sequencing analysis was
performed for 50 subjects (25 major allele homozygotes
and 25 minor allele homozygotes for rs6726395 SNP).
PCR amplification was carried out with 50 ng genomic
DNA and a pair of primers flanking the 2 SNPs by a
GeneAmp PCR System (Applied Biosystems). The pri-
mer sequences were as follows: forward, 5’-AGAGGTTC
TCTTGGGGTTCC-3’; reverse, 5’-AGAACCTTGCCCT
GCTTTTA-3’. The amplified 343-bp PCR DNA pro-
ducts were sequenced using the same primers and the
dideoxynucleotide chain termination method available
as a fluorescent sequencing kit (DNA Sequencing Kit;
Applied Biosystems) and an automated sequencer (ABI
PRISM 3130; Applied Biosystems) according to the
manufacturers’ instruction.
Statistics
Data are expressed as mean ± SD, unless otherwise sta-
ted. Statistical analysis was performed using SYSTAT
software, version 13 (Systat Software, Inc., Chicago, IL).
Statistical tests with a p value < 0.05 were considered
significant.
Values of annual FEV1 decline were computed for
each individual across the repeated measurements using
a linear mixed-effect model. We used a random inter-
cept to take into account the heterogeneity across sub-
jects and the correlation induced by having repeated
observations on the same subjects.
We performed univariate analysis to evaluate associa-
tion of annual decline in FEV1 with clinical characteris-
tics. For categorical variables such as gender and
smoking status, Student’s t tests and one-way analyses of
1,507 participants enrolled 
556 excluded 
without at least 4 valid PFT 
measurements. 
36 had a pulmonary disease 
Old tuberculosis (n=15) including 
3 overlapped with asthma  
Bronchial asthma and/or COPD 
with treatment (n=24) 
915 subjects 
with t 4 PFT measurements over t 4 
years.  
including 47 with asthmatic history, but 
taking no medication for asthma. 
1,471 subjects  
893-896 subjects  
genotyped successfully 
Figure 1 Schematic representation of the study profile.
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for comparisons of 2 and 3 group means, respectively.
For continuous variables such as age, body mass index
(BMI), PFT measurements, and total serum IgE levels,
the correlation with annual decline in FEV1 was assessed
by Pearson correlation coefficient analysis.
All polymorphisms were tested for Hardy-Weinberg
equilibrium using Haploview 4.2 software http://www.
broadinstitute.org/haploview[21]. Estimates of pairwise
linkage disequilibrium (LD) between the loci were calcu-
lated using r
2 [22]. The associations of genotypes with
annual decline in FEV1 were analyzed by multivariate
linear regressions adjusted for potential confounding
f a c t o r ss u c ha ss e x ,a g e ,B M I ,F E V 1/FVC ratio, total
serum IgE levels, smoking status (never, ex, or current),
smoking index (0, 0-200 or > 200), and affection of
bronchial asthma. Correction for multiple comparisons
was done by the Bonferroni’s method. The interaction
effect of genotypes and smoking status on the annual
decline in FEV1 was analyzed using general linear mod-
els adjusted for the same confounding factors except for
smoking behavior.
Association of the rs6726395 genotypes with the
mRNA expression levels of Nrf2 was analyzed using
GENEVAR database http://www.sanger.ac.uk/humgen/
genevar/[23], which shows mRNA expression profiles of
3 cell types (fibroblast, lymphoblastoid cell line and
T-cell) derived from umbilical cords of 75 Geneva Gen-
Cord individuals [24].
For analyses of association between haplotypes and
annual FEV1 decline, we used the Haplo. score program
http://mayoresearch.mayo.edu/mayo/research/biostat/
schaid.cfm, which adjusts for the same covariates and
calculates simulation p values for each haplotype [25].
Results
Characteristics of the study cohort, 915 Japanese indivi-
duals from a general population, are provided in Table 1.
The average number of visits for routine health checkups
over the study period per participant was 9.1 ± 3.7 times
during 11.1 ± 4.6 years. The mean age at the recruitment
was 52.1 years (31-78 years). All the participants were
over 25 years of age at the first visit. Of the participants,
63% were never-smokers, 23% were ex-smokers, and 14%
were current-smokers. The average of serum IgE levels
was 1.78 (log IU/mL) (normal, < 2.23). The mean annual
decline in FEV1 was 23.8 mL/year. The final study popu-
lation included 47 subjects with a history of asthma, but
each of these subjects had not been treated with asthma
medications.
Univariate analysis was performed to evaluate relation-
ships between annual decline in FEV1 and clinical vari-
ables (Table 2). There was no significant difference in
FEV1 decline between men and women. As expected,
the association between annual FEV1 decline and smok-
ing behavior was statistically significant. The mean value
of annual FEV1 declines in current-smokers was signifi-
cantly larger than that in never-smokers. We calculated
smoking index (cigarettes/day × years smoked) for all
the participants and divided the study population into 3
categories; 0, 0-200, and > 200. Mean FEV1 declines in
the 0-200 and > 200 groups were significantly larger
than that in the 0 group. The value of FEV1 decline
showed a weak inverse correlation with FEV1/FVC (r =
-0.278, p < 0.001) and FEV1 % predicted (r = -0.263, p <
0.001). As for the pairwise correlation between annual
FEV1 decline and the other pulmonary function mea-
surements, the correlation coefficients were -0.146 for
FVC % predicted (p < 0.001), -0.144 for FEV1 (p <
0.001), and -0.069 for FVC (p = 0.037). The correlation
coefficients for annual FEV1 decline and age was 0.105
(p = 0.001) and that for annual FEV1 decline and total
IgE levels was 0.097 (p = 0.003).
Genotype analysis at 4 tag SNPs (rs2001350,
rs6726395, rs1962142, rs2364722) and one previously-
reported functional SNP (rs6721961) [16] in the Nrf2
promoter region was attempted for the each partici-
pant. Genotyping of rs2001350 and rs6726395 was suc-
cessful for 895 subjects; similarly, rs1962142 and
rs2364722 genotyping was successful for 896 subjects,
and rs6721961 was for 893 subjects. The overall suc-
cess rate was 97.6-97.9%. All the analyzed SNPs were
Table 1 Characteristics of the participants
a
Characteristic Participants (N = 915)
Age (years) 52.1 ± 8.3
Male sex - N (%) 418 (45.7)
Total duration of follow-up (years) 11.1 ± 4.6
Number of visits 9.1 ± 3.7
BMI 23.1 ± 3.0
FVC (L) 3.12 ± 0.78
FVC % predicted (%) 100.5 ± 13.6
FEV1 (L) 2.56 ± 0.64
FEV1/FVC (%) 82.2 ± 5.6
FEV1 decline (mL/year) 23.8 ± 26.3
Serum IgE (Log IU/mL) 1.78 ± 0.59
Smoking habits - N (%)
Never-smokers 576 (63.0)
Ex-smokers 210 (23.0)
Current-smokers 129 (14.1)
Smoking index
b - N (%)
0 576 (63.0)
0-200 114 (12.5)
> 200 225 (24.6)
Asthma - N (%) 47 (5.1)
a Data are presented as mean ± SD or n (%).
b Smoking index was calculated for current and past smokers by multiplying
smoking dose (cigarettes per day) and duration (years smoked).
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the genotypes and the annual FEV1 decline are shown
in Table 3. Annual FEV1 declines adjusted for potential
confounding factors were significantly different among
rs6726395 genotypes (pcorr = 0.016). The mean annual
FEV1 declines in major allele homozygotes (G/G),
heterozygotes (G/A), and minor allele homozygotes
(A/A) for the rs6726395 SNP were 26.2, 22.3, and 20.8
mL/year, respectively. In contrast, the GENEVAR data-
base did not show a significant difference in Nrf2
mRNA expression levels based on rs6726395 genotypes
(data not shown).
Table 2 Univariate analysis comparing annual decline in FEV1 and clinical variables
Variables Correlation coefficient
a Annual decline in FEV1
Mean ± SD (mL/yr)
P value
Categorical variables
Gender 0.205
Male 25.0 ± 28.2
Female 22.8 ± 24.5
Smoking habits 0.005
Never-smokers 21.7 ± 24.5
Ex-smokers 26.7 ± 27.6
Current-smokers 28.5 ± .30.5*
Smoking index
b 0.006
0 21.7 ± 24.5
0-200 28.2 ± 29.6
> 200 27.0 ± 28.3*
Continuous variables
Age 0.105 0.001
BMI 0.038 0.245
FVC (L) -0.069 0.037
FVC % predicted (%) -0.146 < 0.001
FEV1 (L) -0.144 < 0.001
FEV1 % predicted (%) -0.263 < 0.001
FEV1/FVC (%) -0.278 < 0.001
Serum IgE (Log IU/mL) 0.097 0.003
a Pearson coefficient.
b Smoking index was calculated for current and past smokers by multiplying smoking dose (cigarettes per day) and duration (years smoked).
* p < 0.05 compared with never-smokes (smoking index 0) after Bonferroni post hoc correction.
Table 3 Multivariate linear regressions
a for association between genotypes at the Nrf2 SNPs and decline in FEV1
SNP Genotype N Annual decline in FEV1
Mean ± SD (mL/year)
P value
(corrected p value)
rs2001350 CC 43 24.7 ± 7.5 0.101
CT 296 24.2 ± 7.4
TT 551 23.8 ± 7.9
rs6726395 GG 431 26.2 ± 8.3 0.0031 (0.016)
GA 378 22.3 ± 7.4
AA 86 20.8 ± 8.8
rs1962142 AA 23 28.1 ± 10.4 0.194
AG 277 23.6 ± 6.8
GG 591 24.0 ± 8.0
rs2364722 AA 157 24.9 ± 7.9 0.277
AG 421 24.0 ± 7.4
GG 313 23.4 ± 8.1
rs6721961 GG 496 23.6 ± 7.8 0.900
GT 344 24.5 ± 7.7
TT 53 24.4 ± 7.3
a Adjusted for sex, age, BMI, FEV1/FVC ratio, serum IgE levels, smoking status, smoking index, and asthma diagnosis.
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2) values among the 5 SNPs are shown
in Figure 2. In the present study, the observed LD values
among the 4 tag SNPs detected in the HapMap project
corresponded well with the LD structure that is
expected based on the patterns in the JPT (Japanese)
population of the HapMap group. All the r
2 values
among the 5 SNPs studied did not exceed 0.61, indicat-
ing that these 5 SNPs were not in tight LD with each
other.
Previous results indicate that 3 SNPs (rs6721961,
rs6706649 and rs35652124) in the promoter region of
Nrf2 are functionally relevant [16]. Although it has been
reported that the minor allele of rs6721961 SNP
diminishes promoter activity of the Nrf2 gene, there was
no significant association between this SNP and annual
FEV1 decline in the present study (Table 3). We esti-
mated the extent of linkage disequilibrium between
rs6726395 and the other 2 functional SNPs (rs6706649
and rs35652124) by sequencing 50 subjects. The SNP
rs6726395 was not in tight LD with rs6706649 (r
2 =
0.02) or with rs35652124 (r
2 = 0.67), suggesting that
genetic effects of these 2 functional SNPs do not under-
lie the association of rs6726395 with FEV1 decline. The
SNP rs35652124 was in tight LD (r
2 =0 . 9 2 )w i t h
rs2364722, which did not have a significant association
with annual decline in FEV1 in the present study
(Table 3).
Next, we analyzed effect of interaction between the bi-
allelic SNP rs6726395 and cigarette smoking status on
annual decline in FEV1 (Figure 3). In ex- and current-
smokers, annual FEV1 decline was significantly different
between individuals with and without the rs6726395 G
allele for FEV1 decline. The mean decline values were
27.8 mL/year and 12.5 mL/year in individuals with the
G/G + G/A genotype and those with the A/A genotype,
respectively (p = 0.010). In contrast, the annual FEV1
decline was not significantly different between indivi-
duals carrying the G/G + G/A and the A/A genotypes
(22.7 and 22.8 mL/year, respectively) for individuals who
were never-smokers. The p value for interaction
between rs6726395 and smoking status on the annual
decline in FEV1 was 0.011. These results indicated that
the genetic influence of Nrf2 was modified by smoking
status, suggesting the presence of a gene-environment
interaction in annual decline in FEV1.
We constructed haplotypes composed of the 4 tag
SNPs and rs6721961, and analyzed association of the
haplotypes with annual FEV1 decline (Table 4). The dis-
tribution of the haplotypes was significantly related to
annual FEV1 decline with the global simulation p value
of 0.004. We identified 4 common haplotypes covering
86.8% of the whole genotyped population. The haplo-
type most strongly associated with annual FEV1 decline
was rs2001350T/rs6726395A/rs1962142A/rs2364722A/
rs6721961T with a haplotype score of -2.988 and a
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ciated with lower decline in FEV1.
Discussion
Cigarette smoke (CS) contains a high concentration of oxi-
dants and leads to oxidative stress [7]. In smokers,
increased oxidative stress in the airways is a predominant
cause of accelerated decline in lung function [26,27]. Nrf2
plays a central role in protecting the lung against
CS-induced oxidative stress by up-regulating multiple
genes encoding antioxidant and detoxification proteins,
e.g., heme oxygenase-1, NADPH, and glutathione S-trans-
ferase [12,13]. CS-induced reactive oxygen species produc-
tion via NADPH oxidase activation is involved in the
positive regulation of the Nrf2/ARE pathway. NADPH
oxidase, as a critical regulator of innate immunity, also
limits lung inflammation by attenuating NF-Ba n db y
activating Nrf2[28,29]. On the other hand, CS activates the
NF-B pathway, which participates in the negative regula-
tion of Nrf2/ARE signaling[30,31]. In addition, protein car-
bonylation induced by CS is involved in the suppression of
the Nrf2/ARE pathway[32]. Because several studies have
demonstrated that an Nrf2-dependent adaptive response is
important in preventing CS-induced lung inflammation
and injury[15,33,34], we reasoned that Nrf2 polymorph-
isms have a genetic impact on the CS-induced deteriora-
tion of lung function.
In the present study, we showed that a variant of the
Nrf2 gene was associated with accelerated decline in FEV1
in a general population sample including non-smokers,
moderate smokers, and heavy smokers. A stronger effect
of the rs6726395 SNP on annual FEV1 decline was
observed in smokers than in never-smokers, indicating a
gene-smoking interaction in FEV1 decline. Such an inter-
action is reasonable because Nrf2 activation protects tis-
sues against oxidative stress. The minor allele of
rs6726395 in the homozygous state (A/A) was associated
with a smaller FEV1 decline; therefore, this allele was
thought to be protective against FEV1 decline.
The mechanisms mediating the relationship between
rs6726395 and FEV1 decline were not determined in this
study. Although the rs6726395 SNP is located in the first
intron of the Nrf2 gene, rs6726395 variants did not corre-
late with different Nrf2 mRNA levels according to the
GENEVAR database. However, given that GENEVAR uti-
lizes only three cell types (fibroblast, lymphoblastoid cell
line and T-cell), the possibility remains that rs6726395 has
some genetic influence onNrf2transcriptional activity in
alveolar macrophages because Nrf2 appears to exert its
protective effects through the transcriptional activation of
antiprotease and antioxidant genes in alveolar macro-
phages[14]and its mRNA expression is decreased in
macrophages of COPD patients[15]. As the rs6726395
SNP was not in significant LD with any of the 3 functional
SNPs known to reside in the promoter region, rs6726395
may be in LD with other causal SNPs in or nearby the
Nrf2 gene; the allele responsible for the protective effects
observed in this study could be on the extended
rs2001350T/rs6726395A/rs1962142A/rs2364722A/rs6
721961T haplotype. We have not comprehensively
assessed the genetic variation in Nrf2, and the functional
impact of the Nrf2 SNPs carried on different haplotypes is
still unknown. The identification of functional variants in
Nrf2 loci will require fine mapping efforts using large
populations. However, the lack of suitable Japanese
cohorts with the measurements of annual decline in FEV1
and genomic DNA samples available for genotyping pre-
vented us from performing a replication of this study on
the association of rs6726395 with FEV1 decline.
In the present study, the annual declines in FEV1 were
estimated by longitudinal retrospective measurements.
The natural course of FEV1 over time is divided into
three phases; a lung growth phase occurs during child-
hood and adolescence, this grow phase is followed by a
plateau phase, and a decline phase begins at about 25
years of age [35]. The level of FEV1 at a given time in
adulthood is affected by any deterioration that occurred
in any of these 3 phases. Because we planned to analyze
the effects of oxidative stress caused by cigarette smok-
ing on lung function, FEV1 decline over time calculated
in a longitudinal study was more valuable than absolute
values of pulmonary function measurements in a cross-
sectional study. As the ages of all the participants in this
study were over 25 years at the first visit, all the subjects
w e r et h o u g h tt ob ei nt h ed e c l i n ep h a s eo fl u n g
function.
Siedlinski et al. [17] have reported that the heterozygote
genotype of rs2364723, which is in the first intron of Nrf2,
Table 4 Estimated haplotype frequencies and haplotype association with annual decline in FEV1
Haplotype rs2001350 rs6726395 rs1962142 rs2364722 rs6721961 Haplotype
frequency
Haplotype-
specific score
Simulation p
value
Global simulation
p value
1 T A A A T 0.082 -2.988 0.002 0.004
2 C G A G T 0.148 -1.319 0.182
3 T A G A G 0.561 0.453 0.663
4 T A A A G 0.077 1.184 0.235
Haplotype frequencies were estimated using the Haplo. Stats program. Haplotype 1(rs2001350T/rs6726395A/rs1962142A/rs2364722A/rs6721961T) was associated
with annual decline in FEV1 with a haplotype score of -2.988 and a simulation p value of 0.002. Haplotye with frequencies less than 0.05 were excluded.
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Page 7 of 9is associated with a lower level of FEV1 in Caucasian smo-
kers. However, they showed no relationship between
rs2364723 and annual decline in FEV1. Because rs2364723
is in complete LD with rs2364722 (r
2 = 1.00) in the JPT
population of the HapMap group, the finding from the
Siedlinski et al. investigation may be compatible with the
result from the present study. Our results are also consis-
tent with findings from a previous Japanese case-control
association study that showed no relationship between the
3 previously identified functional SNPs in the promoter
region (rs6721961, rs6706649, and rs35652124) and sus-
ceptibility to COPD [36]. Recently, two large-scale gen-
ome-wide association studies have identified several loci
associated with FEV1 and FEV1/FVC ratio [10,11]. Reports
from the studies included lists of the top 2,000 SNPs
related to the pulmonary function measurements. SNPs in
or nearby the Nrf2 gene including the SNPs in the current
study were not among these top 2,000 SNPs.
I no r d e rt oe n s u r ear e l i a b l ee s t i m a t eo fF E V 1 decline,
we selected the subjects who provided at least 4 valid PFT
measurements over a period of at least 4 years. Variation
in the follow-up periods and the numbers of visits could
contribute to bias in estimations of annual FEV1 decline;
therefore, we used a linear mixed-effects model to control
for correlations among repeated measures from each sub-
ject. Moreover, inhaled corticosteroids, leukotriene recep-
tor antagonists, and bronchodilators (e.g., b-adrenoceptor
stimulants and anticholinergic agents) can improve FEV1
measurements in asthmatic and/or COPD subjects; there-
fore, we excluded those subjects with a history of asthma
and/or COPD treated with these medications during the
retrospective study period. Nevertheless, because this
study was retrospective, attrition could affect the estima-
tion of FEV1 decline. Subjects with accelerated decline in
FEV1 are more likely to drop out from the annual health
checkup. However, as attrition is likely to result in an
underestimate of annual FEV1 decline, it would bias the
study against finding an effect.
Conclusions
We demonstrated an association between a SNP
(rs6726395) in the first intron of the Nrf2 gene and annual
decline in FEV1. In smokers, individuals carrying the
major allele of this SNP showed greater decline in FEV1
than those homozygous for the minor allele; however, this
effect was not seen in never-smokers. Although the direct
functional effect of rs6726395 on the Nrf2 gene is
unknown, this risk allele may be useful as a clinical marker
for identifying individuals particularly susceptible to loss of
lung function due to cigarette smoking. Our study sug-
gests that pharmacological activation of Nrf2 by chemo-
preventive and phytochemical agents may be the strategy
capable of exerting protective effects against various stress
conditions including increased annual decline in FEV1as-
sociated with CS.
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